Clinical Trial Update: Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, pharmacokinetics, and antitumor activity of BGB-A317 in participants with advanced cancer concluded with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• BGB-A317 (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Advanced Cancer | Phase 1 | Status: COMPLETED | Results posted: 2021-11-17